“…Further derivatization of dihydroberberine by the introduction of hydroxy and cyano groups onto the reduced ring leads to active antimalarials (Vennerstrom & Klayman, 1988), avian myeblastosis virus inhibitors (AMV–RT) (Kusumoto et al , 1991), antitumour agents (Kim et al , 1997), antifungals (Dostál et al , 1999), mitogen-activated protein kinase inhibitors (MAPKK) (Jang et al , 2002), promoters of glucose metabolism and insulin secretion (Xu et al , 2011), and CD36 antagonists (Li et al , 2010). Dihydroberberine has found use as an intermediate in the synthesis of substituted berberine analogues which were found to act as anticancer agents (Zhang et al , 2012), pancreatic lipase inhibitory agents (Mohammad et al , 2013), antifungal agents (Li et al , 2013), Toxoplasma gondii inhibitors (Krivogorsky et al , 2012), and mitochondria-targeted antioxidants (Lyamzaev et al , 2011), and which have shown activity as antibabesial (Subeki et al , 2005) and antileishmania agents (Marquis et al , 2003) and as HIV-1 RT inhibitors (Vennerstrom et al , 1990). …”